Stock Market Reviews

ROIV (Roivant Sciences Ltd.) News

Get the latest news, insights, and market updates on ROIV (Roivant Sciences Ltd.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Leerink Raises Price Target as Roivant (ROIV) Accelerates Drug Development Pipeline
  Roivant Sciences Ltd. (NASDAQ:ROIV) ranks among the best stocks under $25 to buy now. Following the company’s analyst meeting on December 11, Leerink Partners boosted its price target for Roivant Sciences Ltd. (NASDAQ:ROIV) to $32 from $29, keeping an Outperform rating on the company’s shares. The firm highlighted lower estimated operational expenses in the years […]
  Jan 2, 2026 - $ROIV
• Insider Confidence In December 2025's Leading Growth Companies
  As the U.S. stock market continues to reach new heights, with the S&P 500 setting an all-time high and major indices logging consecutive gains, investors are increasingly attracted to companies that demonstrate robust growth potential and strong insider confidence. In this thriving environment, stocks with high insider ownership often signal a deep commitment from those who know the company best, suggesting alignment with shareholder interests and potential resilience in times of market...
  Dec 26, 2025 - $ROIV
• Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million?
  Focused on monoclonal antibody therapies for autoimmune diseases, this biotech just reported a significant insider buy in public filings.
  Dec 18, 2025 - $ROIV
• US High Growth Tech Stocks To Watch December 2025
  As the United States market navigates a period of volatility, with major indexes closing lower amid concerns over an AI bubble and looming economic reports, investors are keenly observing the tech sector's dynamics. In such a climate, identifying high-growth tech stocks involves looking for companies with strong fundamentals and resilience to market pressures.
  Dec 17, 2025 - $ROIV
• Immunovant (IMVT) Is Up 14.0% After Roivant-Backed $550 Million Equity Raise For IMVT-1402 - Has The Bull Case Changed?
  Immunovant recently completed a US$550.20 million follow-on equity offering, issuing 26,200,000 common shares at US$21.00 each with a US$0.63 discount per share, to help fund development and a potential commercial launch of its lead candidate IMVT-1402 for Graves’ disease and other autoimmune conditions. A striking element of the deal is controlling shareholder Roivant Sciences committing around US$349.90 million for 16,666,666 shares, reinforcing Immunovant’s financing plans as it prepares...
  Dec 15, 2025 - $ROIV
• Immunovant Announces Pricing of $550 Million Common Stock Financing
  Funding to provide runway through potential Graves’ Disease commercial launch NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten offering of its common stock, with anticipated gross proceeds to Immunovant of approximately $550 million, before deducting underwriting discounts and commissions and other expenses payable
  Dec 11, 2025 - $ROIV
• Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day
  Roivant enters new phase of corporate journey with 3+ launches, 4+ NDA/BLA filings, 8+ pivotal and 3+ proof-of-concept study readouts expected over the next three yearsHighlighting clinical execution, Roivant announces positive updates to timing guidance across four key programs: Brepocitinib NDA filing in dermatomyositis (DM) now expected in early calendar year 2026; commercial preparation underway with launch expected early in calendar year 2027Brepocitinib Phase 3 trial in non-infectious uvei
  Dec 11, 2025 - $ROIV
• A Roivant spinout bets on AI-designed drugs for immune conditions
  PsiThera, formerly Psivant Therapeutics, raised just over $47 million for oral drugs targeting “diseases long-constrained by injectable-only approaches."
  Dec 10, 2025 - $ROIV
• Top Growth Companies With Strong Insider Ownership For November 2025
  As the U.S. stock market experiences a significant upswing, with major indexes like the Nasdaq and S&P 500 posting notable gains, investors are keenly observing growth companies that exhibit strong insider ownership. In such a buoyant market environment, stocks where company insiders hold substantial stakes can be appealing as they often signal confidence in the company's future prospects and alignment of interests with shareholders.
  Nov 26, 2025 - $ROIV
• Will Roivant Sciences’ (ROIV) Slowing Revenue Growth Shape Its Long-Term Innovation Story?
  Roivant Sciences Ltd. recently reported earnings for the second quarter and six months ended September 30, 2025, revealing quarterly sales of US$1.57 million and a quarterly net loss of US$113.52 million, both down from the prior year period. While the company's net loss for the quarter narrowed compared to last year, the steep decline in six-month sales and larger cumulative net loss highlight ongoing challenges in generating revenue growth. We'll examine how Roivant's six-month sales drop...
  Nov 11, 2025 - $ROIV